RAICHUR, Indien, 13. März 2025 /PRNewswire/ — Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), ein führender Hersteller von Wirkstoffen und Formulierungen, gibt bekannt, dass der Sachverständigenausschuss (SEC) der CDSCO sein neues Prüfpräparat (Investigational New Drug, IND) […]
RAICHUR, India , March 12, 2025 /PRNewswire/ — Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug (IND) […]
RAICHUR, Inde, 12 mars 2025 /PRNewswire/ — Shilpa Medicare Limited (BSE : 530549) (NSE : SHILPAMED), l’un des principaux fabricants d’IPA et de formulations, annonce que le comité d’experts du domaine (SEC) de la CDSCO a approuvé son […]
RAICHUR, India , March 12, 2025 /PRNewswire/ — Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug (IND) […]
